Moderna, Inc. (MRNA)

Market Cap	15.16B
Revenue (ttm)	5.08B
Net Income (ttm)	-2.22B
Shares Out	384.82M
EPS (ttm)	-5.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,021,445
Open	39.20
Previous Close	39.56
Day's Range	39.12 - 40.83
52-Week Range	35.80 - 170.47
Beta	1.59
Analysts	Hold
Price Target	79.50 (+101.83%)
Earnings Date	Feb 20, 2025

About MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vac...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 7, 2018
• Employees: 5,600
• Stock Exchange: NASDAQ
• Ticker Symbol: MRNA
• Website: https://www.modernatx.com

Analyst Forecast

According to 19 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $79.5, which is an increase of 101.83% from the latest price.

Price Target

$79.5

(101.83% upside)

Analyst Consensus: Hold